Publication of SARA-INT Phase II results for BIO101Confirmation of Phase 3 readinessParis, France and Cambridge, Massachusetts--(Newsfile Corp. - March 17, 2025) - Biophytis SA (FP: ALBPS) ("Biophytis ...

Sarcopenia influences toxicity and survival in non-small cell lung cancer, and sarcopenia assessment can be factored into ...

While a gradual loss in muscle strength is a natural part of aging, for many older adults it’s more than just feeling a ...

Researchers enhance sarcopenia treatment by analyzing gut bacteria and genetics Personalized strategies are essential for ...

A new study suggests that a small molecule drug that targets a specific serotonin receptor could become the first ...

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...

Allosteric Bioscience, Inc. (ABI), has announced today that it has licensed technology from Johns Hopkins University for the treatment or prevention of sarcopenia which is a serious medical ...

Epirium Bio Inc. (Epirium), a clinical stage biopharmaceutical company advancing medicines for neuromuscular and fibrotic diseases, today announced the upcoming presentation of two scientific posters ...

On average, individuals in their 30s and 40s lose about 1–2% of their muscle mass per year, which only goes up as they age ...